biostudies-literatureUnknown10(3)Kitada MMitsubishi Tanabe Pharma<h4>Aims/introduction</h4>The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease.<h4>Materials and methods</h4>The present study was a single-arm, open-label, observational study. A total of 23 patients, who had urinary albumin/creatinine ratios (UACR) ≥30 mg/gCr in their first urine in the early morning, and received other DPP-4 inhibitors and renin-angiotensin system inhibitors, switched to teneligliptin 20 mg/day. After switching to teneligliptin for 24 weeks, we evaluated changes in glycated hemoglobin (HbA1c), fasting plasma glucose levels, plasma DPP-4 activity and UACR.<h4>Results</h4>HbA1c,Journal of diabetes investigation706-713https://www.ebi.ac.uk/biostudies/studies/S-EPMC6497591biostudies-literatureEffect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.PMC6497591Ogura YKoya DNakagawa AKanasaki KNitta KFujii MKitada MKonishi KIida YfalseEffect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.<h4>Aims/introduction</h4>The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease.<h4>Materials and methods</h4>The present study was a single-arm, open-label, observational study. A total of 23 patients, who had urinary albumin/creatinine ratios (UACR) ≥30 mg/gCr in their first urine in the early morning, and received other DPP-4 inhibitors and renin-angiotensin system inhibitors, switched to teneligliptin 20 mg/day. After switching to teneligliptin for 24 weeks, we evaluated changes in glycated hemoglobin (HbA1c), fasting plasma glucose levels, plasma DPP-4 activity and UACR.<h4>Results</h4>HbA1c,2019-01-01T00:00:00Z2019 May2025-04-19T22:54:20.338Z2019-06-06T23:10:36ZS-EPMC64975913013638410.1111/jdi.12917